ICC4 BioVector?人膽道癌 (肝內(nèi)膽管癌)細(xì)胞系MGH-ICC4 human biliary tract cancer cell line
- 價(jià) 格：￥99860
- 貨 號(hào)：BioVector?- ICC4
- 產(chǎn) 地：北京
- BioVector NTCC典型培養(yǎng)物保藏中心
- 聯(lián)系人：Dr.Xu, Biovector NTCC Inc.
電話：400-800-2947 工作微信:1843439339 (QQ同號(hào))
手機(jī)：18901268599
地址：北京
- 已注冊(cè)
BioVector? ICC4（別名：MGH-ICC4）人膽道癌 (肝內(nèi)膽管癌)細(xì)胞系
中文版：ICC4 細(xì)胞系數(shù)據(jù)表
| 參數(shù) | 詳細(xì)信息 |
|---|---|
| 細(xì)胞名稱 | ICC4 (別名：MGH-ICC4) |
| DSMZ 編號(hào) | ACC 996 |
| 物種來源 | 人類 (Homo sapiens) |
| 細(xì)胞類型 | 膽道癌 (肝內(nèi)膽管癌) |
| 起源背景 | 2016年建立。源自一名經(jīng)過前期治療的 61 歲男性的肝內(nèi)膽管癌脊柱轉(zhuǎn)移灶。該細(xì)胞系是從患者來源的異種移植模型 (PDX) 中建立的。 |
| 遺傳特征 | 攜帶以下基因突變：TP53 p.L137Q、ARID1A p.G410Ter、BAP1 p.I586NfsTer54。此外還存在 TSPAN6 缺失和 MUC4 突變/缺失。 |
| 形態(tài)特征 | 類上皮細(xì)胞；貼壁呈單層生長(zhǎng) |
| 生長(zhǎng)特性 | 貼壁生長(zhǎng) |
| 倍增時(shí)間 | 約 48-72 小時(shí) |
| 培養(yǎng)基配方 | 90% RPMI 1640 + 10% 熱滅活胎牛血清 (h.i. FBS) |
| 傳代方法 | 在 T75 瓶中以約 1 x 10? 細(xì)胞接種；每周傳代 1-2 次，比例為 1:5 (使用胰酶/EDTA) |
| 細(xì)胞產(chǎn)量 | 每個(gè) T75 瓶約可收獲 10 x 10? 個(gè)細(xì)胞 |
| 身份驗(yàn)證 | 通過 STR 分析驗(yàn)證，與參考數(shù)據(jù)庫一致；端粒酶活性陽性。 |
| 生物安全等級(jí) | 1 級(jí) |
English Version: ICC4 Cell Line Datasheet
| Parameter | Information |
|---|---|
| Name | ICC4 (Alias: MGH-ICC4) |
| DSMZ No. | ACC 996 |
| Organism | Human (Homo sapiens) |
| Cell Type | Biliary tract cancer (Intrahepatic cholangiocarcinoma) |
| Origin | Established in 2016 from a spine metastasis PDX model of a 61-year-old pretreated male with intrahepatic cholangiocarcinoma. |
| Genetic Profile | Confirmed mutations: TP53 p.L137Q, ARID1A p.G410Ter, BAP1 p.I586NfsTer54. Also features TSPAN6 deletion and MUC4 mutations/deletions. |
| Morphology | Epithelioid; adherent monolayer |
| Growth Mode | Adherent |
| Doubling Time | Approximately 48–72 hours |
| Culture Medium | 90% RPMI 1640 + 10% Heat-inactivated FBS (h.i. FBS) |
| Subculturing | Seed at ~1 x 10? cells/T75; split 1:5 once or twice a week using Trypsin/EDTA. |
| Harvest Yield | Approx. 10 x 10? cells per T75 flask |
| Authenticity | Confirmed via STR DNA profiling; positive for telomerase activity. |
| Biosafety Level | 1 |
Core Characteristics / 核心研究?jī)r(jià)值
Metastatic Model: ICC4 is uniquely valuable as a model derived from spine metastasis, providing insights into the metastatic niche and progression of biliary tract cancers.
Genetic Complexity: The co-occurrence of BAP1, ARID1A, and TP53 mutations reflects a highly aggressive genomic profile common in advanced intrahepatic cholangiocarcinoma.
病毒檢測(cè)： PCR 檢測(cè)結(jié)果顯示 EBV, HBV, HCV, HIV, HTLV-1/2 以及 MLV 均為陰性。
Supplier生產(chǎn)廠家:
BioVector NTCC質(zhì)粒載體菌種細(xì)胞蛋白抗體基因保藏中心
BioVector NTCC Inc.
TEL: 400-800-2947
E-mail: [email protected]
工作微信/QQ同號(hào): 1843439339
您正在向 biovector.net 發(fā)送關(guān)于產(chǎn)品 ICC4 BioVector?人膽道癌 (肝內(nèi)膽管癌)細(xì)胞系MGH-ICC4 human biliary tract cancer cell line 的詢問
- 公告/新聞
